ETF comparison

IBB vs XLV

Both Healthcare.

iShares Biotechnology ETF · State Street Health Care Select Sector SPDR ETF

Holdings overlap

Weighted by ISIN/CUSIP
11.9 %

9 positions appear in both funds. Buying equal dollars of IBB and XLV would leave roughly 11.9% of each dollar exposed to the same underlying securities.

IBB only 97.8% Shared 11.9% XLV only 87.9%
In IBB only
247 positions
Shared
9 positions
In XLV only
51 positions

Side by side

IBB

iShares Biotechnology ETF

iShares · Healthcare

69 composite / 100
Expense ratio
0.44%
Net assets
$9.09B
TTM yield
0.22%
Top-10 conc.
54.7%
XLV

State Street Health Care Select Sector SPDR ETF

State Street · Healthcare

83 composite / 100
Expense ratio
0.080%
Net assets
$40.60B
TTM yield
1.60%
Top-10 conc.
59.1%

Sub-score comparison

56
Cost
92
85
Tax efficiency
82
98
Liquidity
100
36
Concentration
30
Tracking quality
IBB sub-score XLV

Tracking quality isn't part of the composite — see what we don't score for why.

Cost difference

XLV is 36 bps cheaper than IBB. On a $100,000 position that's about $360/yr more in fees for IBB.

Fee figure is the annual expense charged on $100,000. To see how the gap compounds over a multi-decade holding period, open the cost calculator pre-filled with IBB vs XLV.

Top shared holdings

9 shared in total
# Holding In IBB In XLV Overlap
1 Amgen, Inc. 7.51% 3.57% 3.57%
2 Gilead Sciences, Inc. 7.75% 3.26% 3.26%
3 Vertex Pharmaceuticals, Inc. 7.44% 2.14% 2.14%
4 Regeneron Pharmaceuticals, Inc. 7.21% 1.47% 1.47%
5 Biogen, Inc. 2.46% 0.51% 0.51%
6 Moderna, Inc. 1.68% 0.33% 0.33%
7 Incyte Corp. 1.70% 0.30% 0.30%
8 Charles River Laboratories International, Inc. 0.77% 0.16% 0.16%
9 Bio-Techne Corp. 0.74% 0.15% 0.15%

Only in IBB

247 total
  • BlackRock Funds III 9.66%
  • Alnylam Pharmaceuticals, Inc. 3.99%
  • Insmed, Inc. 3.20%
  • Argenx SE 3.07%
  • Natera, Inc. 2.41%
  • United Therapeutics Corp. 2.30%
  • BeOne Medicines Ltd. 1.93%
  • Illumina, Inc. 1.68%
  • Revolution Medicines, Inc. 1.54%
  • Roivant Sciences Ltd. 1.24%

Only in XLV

51 total
  • Eli Lilly & Co 13.74%
  • Johnson & Johnson 11.10%
  • AbbVie Inc 7.25%
  • Merck & Co Inc 5.63%
  • UnitedHealth Group Inc 4.62%
  • Thermo Fisher Scientific Inc 3.48%
  • Abbott Laboratories 3.37%
  • Intuitive Surgical Inc 3.09%
  • Pfizer Inc 3.01%
  • Bristol-Myers Squibb Co 2.33%

Open IBB or XLV at a brokerage

Both funds trade commission-free at major US brokerages.

Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.

Holdings overlap is the sum of min(weight_a, weight_b) over positions matched on ISIN (CUSIP fallback). Methodology: see /methodology/.

Comparing two funds doesn't endorse swapping one for the other. Tax-lot history, account type, and personal goals matter — PlainIndex publishes data and methodology, not investment advice.